Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.82 |
| ▸ | LMNA | P02545 | 7/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.57 |
| ▸ | RELA | Q04206 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | NAMPT | P43490 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28859518 | 0.98 | L3MBTL1 (0.80) | L3MBTL1LMNAALDH1A1KMT2AMAPT | |
| Cyclohexane SCHEMBL27726328 | 0.95 | L3MBTL1 (0.76) | L3MBTL1LMNAALDH1A1KMT2AMAPT | |
| Ethyl Nicotinate SCHEMBL7864950 | 0.95 | L3MBTL1 (0.76) | L3MBTL1LMNAALDH1A1KMT2AMAPT | |
| SCHEMBL551716 | 0.90 | L3MBTL1 (1.00) | L3MBTL1LMNAALDH1A1KMT2AMAPT | |
| SCHEMBL25009812 | 0.90 | L3MBTL1 (0.76) | L3MBTL1LMNAALDH1A1KMT2AMAPT | |
| SCHEMBL30556174 | 0.90 | L3MBTL1 (0.76) | L3MBTL1LMNAALDH1A1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL5559952 | 0.89 | L3MBTL1 (0.97) | L3MBTL1LMNAALDH1A1KMT2AMAPT | |
| SCHEMBL551811 | 0.89 | LMNA (0.97) | L3MBTL1LMNAALDH1A1KMT2AMAPT | |
| SCHEMBL9717064 | 0.88 | LMNA (1.00) | L3MBTL1LMNAALDH1A1KMT2AMAPT | |
| SCHEMBL589021 | 0.88 | LMNA (1.00) | L3MBTL1LMNAALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 331 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122011067-A | Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and using the same | 麦德龙国际生物科技有限责任公司 | 2026-05-12 | — | — | CN | claimed |
| CN-118994269-A | Preparation method of beta-nicotinamide mononucleotide | 上海昶法新材料有限公司 | 2024-11-22 | — | — | CN | claimed |
| EP-4346842-A1 | CRYSTALLINE SOLIDS OF NICOTINIC ACID MONONUCLEOTIDE AND ESTERS THEREOF AND METHODS OF MAKING AND USE | Metro International Biotech, LLC (US) | 2024-04-10 | — | — | EP | claimed |
| CN-117545488-A | Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and using the same | 麦德龙国际生物科技有限责任公司 | 2024-02-09 | — | — | CN | claimed |
| US-11787830-B2 | Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use | METRO INTERNATIONAL BIOTECH, LLC (US) | 2023-10-17 | — | — | US | claimed |
| US-20230257412-A1 | CRYSTALLINE SOLIDS OF NICOTINIC ACID MONONUCLEOTIDE AND ESTERS THEREOF AND METHODS OF MAKING AND USE | METRO INTERNATIONAL BIOTECH, LLC | 2023-08-17 | — | — | US | claimed |
| CN-116444581-A | Beta-nicotinamide mononucleotide and preparation method thereof | 上海昶法新材料有限公司 | 2023-07-18 | — | — | CN | claimed |
| WO-2022251491-A1 | CRYSTALLINE SOLIDS OF NICOTINIC ACID MONONUCLEOTIDE AND ESTERS THEREOF AND METHODS OF MAKING AND USE | METRO INTERNATIONAL BIOTECH, LLC (US) | 2022-12-01 | — | — | WO | claimed |
| CN-113527376-A | Preparation method of beta-nicotinamide mononucleotide | 上海昶法新材料有限公司 | 2021-10-22 | — | — | CN | claimed |
| EP-1517880-B1 | PRODUCTION OF CIS-PELLITORIN AND USE AS A FLAVOURING | SYMRISE AG (DE) | 2011-01-05 | — | — | EP | claimed |
| US-20050100588-A1 | Self-adhesive matrix plaster containing an active ingredient and based on polyurethane gels | BEIERSDORF AG | 2005-05-12 | — | — | US | claimed |
| EP-1335715-B1 | SKIN-FRIENDLY AND DRUG-CONTAINING PATCHES FOR TRANSDERMAL ADMINISTRATION OF HYPEREMIC ACTIVE INGREDIENTS | BEIERSDORF AG (DE) | 2005-05-11 | — | — | EP | claimed |
| WO-2005002554-A2 | A METHOD OF PROMOTING SLEEP USING TOPICAL ADMINISTRATION OF VASOACTIVE AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 2005-01-13 | — | — | WO | claimed |
| US-20040254202-A1 | Method of promoting sleep using topical administration of vasoactive agents | THE PROCTER & GAMBLE COMPANY | 2004-12-16 | — | — | US | claimed |
| US-20040009215-A1 | Skin friendly active substance patch for transdermal administration of hyperemic active substances | BEIERSDORF AG | 2004-01-15 | — | — | US | claimed |
| EP-0846463-B1 | Active substance containing plaster | BEIERSDORF AG (DE) | 2003-02-26 | — | — | EP | claimed |
| WO-2001019185-A2 | METHODS FOR CONTROLLING A PEST POPULATION | SUMMUS GROUP, LTD. (US) | 2001-03-22 | — | — | WO | claimed |
| US-5939568-A | Accelerated catalysis of olefinic epoxidations | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-08-17 | — | — | US | claimed |
| WO-1998033786-A1 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-08-06 | — | — | WO | claimed |
| US-5629002-A | THIOCYANATES IN SYNERGISTIC COMBINATION WITH ESTROGENS, SULFUR, SULFIDES, VASODILATORS, PROTEIN HYDROLYZATES, AMINO ACIDS, CARBOXYLIC ACIDS, VITAMINS | WEUFFEN WOLFGANG (DE) | 1997-05-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050100588-A1 | Self-adhesive matrix plaster containing an active ingredient and based on polyurethane gels | PLOD3, COL14A1, LCP1 | L3MBTL1 4499/4885LMNA 1872/4885ALDH1A1 1266/4885 |
| US-11787830-B2 | Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use | PNP, NAPRT, NAMPT | L3MBTL1 2519/4885LMNA 216/4885ALDH1A1 3291/4885 |
| US-20040009215-A1 | Skin friendly active substance patch for transdermal administration of hyperemic active substances | CUTA, CD44, DSG1 | L3MBTL1 4379/4885LMNA 1587/4885ALDH1A1 2678/4885 |
| US-20230257412-A1 | CRYSTALLINE SOLIDS OF NICOTINIC ACID MONONUCLEOTIDE AND ESTERS THEREOF AND METHODS OF MAKING AND USE | PNP, NAPRT, NAMPT | L3MBTL1 2519/4885LMNA 216/4885ALDH1A1 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.